KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Cash from Financing Activities (2016 - 2025)

Pacira BioSciences has reported Cash from Financing Activities over the past 16 years, most recently at -$51.7 million for Q4 2025.

  • Quarterly results put Cash from Financing Activities at -$51.7 million for Q4 2025, down 2542.05% from a year ago — trailing twelve months through Dec 2025 was -$369.6 million (down 2228.82% YoY), and the annual figure for FY2025 was -$369.6 million, down 2228.82%.
  • Cash from Financing Activities for Q4 2025 was -$51.7 million at Pacira BioSciences, up from -$257.5 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for PCRX hit a ceiling of $361.4 million in Q4 2021 and a floor of -$257.5 million in Q3 2025.
  • Median Cash from Financing Activities over the past 5 years was -$2.9 million (2024), compared with a mean of -$27.8 million.
  • Biggest five-year swings in Cash from Financing Activities: soared 5577.27% in 2024 and later crashed 8950.12% in 2025.
  • Pacira BioSciences' Cash from Financing Activities stood at $361.4 million in 2021, then tumbled by 116.19% to -$58.5 million in 2022, then skyrocketed by 96.96% to -$1.8 million in 2023, then fell by 9.89% to -$2.0 million in 2024, then crashed by 2542.05% to -$51.7 million in 2025.
  • The last three reported values for Cash from Financing Activities were -$51.7 million (Q4 2025), -$257.5 million (Q3 2025), and -$57.5 million (Q2 2025) per Business Quant data.